Case Report
Ependymoma as a Secondary Malignancy after Treatment of Non- Hodgkin Lymphoma
Mehran K1, Zareifar S1, Mandana T2, Babak A3*, Afsaneh H3, Karmella K1 and Maral M11Shiraz University of Medical Science, Shiraz, Iran
2Paediatric Haematologist Oncologist, Hematology Oncology, Mahak Hospital-Tehran, Iran
3Hematology Oncology, Lorestan University of Medical Science, Khoramabad, Iran
- *Corresponding Author:
- Babak Abdolkarimi
Hematology Oncology
Lorestan University of Medical Science
Khoramabad, Iran
Tel: +989183605274
E-mail: b.abdolkarimi@yahoo.com
Received Date: July 13, 2016; Accepted Date: January 21, 2017; Published Date: January 27, 2017
Citation: Mehran K, Zareifar S, Mandana T, Babak A, Afsaneh H, et al. (2017) Ependymoma as a Secondary Malignancy after Treatment of Non- Hodgkin Lymphoma. OMICS J Radiol 6:247. doi: 10.4172/2167-7964.1000247
Copyright: © 2017 Mehran K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Therapeutic advances in the treatment of paediatric neoplasms have improved the prognosis but have also increased the risk of developing rare second malignant neoplasms (SMNs) in late period after chemotherapy or radiation course. We are going to report a patient therapy-related solid tumors (brain ependymoma after non Hodgkin lymphoma) short latency period after primary tumor which is a rare case among secondary tumors. After 4 years from lymphoma involvement a mediastinal mass revealed in CXR in favor of relapse in follow up period. The key point of this case is that secondary solid malignancy followed infiltrative malignancy despite of similar cases that infiltrative malignancy followed solid tumor and without radiation therapy.
